Limitations in Identifying and Managing HBR Patients Undergoing PCI

A deficit of randomized PCI data including the high bleeding risk population makes it challenging to define the optimal management of these patients.

By Thomas Cuisset, MD

Key Factors for Clinical Decisions When Treating Patients at High Bleeding Risk

Less is more when treating high bleeding risk patients with latest-generation DESs and short DAPT duration.

By Michel Zeitouni, MD, and Gilles Montalescot, MD, PhD

Clinical Decision-Making When Treating High Bleeding Risk Patients: A Japanese Perspective

By Kazushige Kadota, MD, PhD

The Role of Stent Biomaterials In Reducing DAPT Duration

Expert commentary on the roles of technology and pharmacology.

By Hiroyuki Jinnouchi, MD; Renu Virmani, MD; and Aloke V. Finn, MD

Case Report: Antiplatelet Therapy After Complex PCI in the Anticoagulated Patient

By Michael P. Savage, MD, FACC, FSCAI, FACP; David L. Fischman, MD, FACC, FACP; and Marguerite Davis, BS, RT(R), RCIS